The Association Between Serum HBsAg Combined With HBVDNA In PBMCs And Anti-HBV Treatment Response Of Enticavir

Objective The aim of this study was to prectict the efficacy of enticavir by the changes of HBVDNA in PBMCs and serum HBsAg in HBeAg-positive chronic hepatitis B patients treated with Entecavir.Methods 77 cases of HBeAg-positive chronic hepatitis B patients were randomly divided into control group (40 cases) and treatment group (37 cases), treatment group received entecavir 0.5 mg/day treatment> 48 weeks.Hepatitis B serology marker. HBVDNA in serum and PBMCs and Quantitative serum HBsAg were assessed at baseline, during treatment (weeks 4,12,24,and 48).Results HBVDNA in serum and PBMCs conversion rate was significantly higher in treatment group than in control group at 48 weeks.In treatment group.the detection rate of HBVDNA in PBMCs from patients with HBVDNA positive was 78.4%.. Serum HBVDNA and PBMCs HBVDNA positive rate decreased with the prolonged course of treatment.The patients with negative HBVDNA in PBMCs in initial treatment had a higher seroconversion rate than patients with positive HBVDNA in PBMCs in initial treatment (p<0.05).The patients with low serum HBsAg in initial treatment was prone to HBeAg seroconversio.Conclusion HBVDNA in PBMCs and serum was significantly inhibited by Entecavir having no significant effect on serum HBsAg.HBVDNA conversion in PBMCs and low serum HBsAg in initial treatment had a certain value in predicting E antigen seroconversion.